Loading
Five years on, the benefit of adjuvant capecitabine and oxaliplatin held and translated into longer survival: 78 percent alive against 69 percent with surgery alone.
Five-year follow-up of the CLASSIC trial (1,035 patients) at a median of 62.4 months: disease-free survival events in 27 percent of chemotherapy patients against 39 percent of observation patients (hazard ratio 0.58); estimated five-year disease-free survival 68 against 53 percent and overall survival 78 against 69 percent (hazard ratio 0.66).
Confirms a survival benefit for adjuvant CAPOX after D2 gastrectomy.
Shares CLASSIC, Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer.
Shares Oxaliplatin, Capecitabine.
Shares Oxaliplatin, Capecitabine.